Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04035980

Recruitment Status : Recruiting

First Posted : July 29, 2019

Last Update Posted : July 29, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Manuel Hernandez-Guerra, MD, University of La Laguna

Study Description

Brief Summary:

The investigators have designed a community-based intervention study to all subjects attended in drug addiction centers screened for hepatitis C virus (HCV) to evaluate the efficacy and acceptance of a telemedicine based programme versus conventional healthcare assistance

Condition or disease	Intervention/treatment	Phase
Hepatitis C Virus Infection	Behavioral: Telemedicine based healthcare programme	Not Applicable

Show detailed description

Detailed Description:

Our current programme of engagement to healthcare and HCV screening based on on-site dried blood spot (DBS) testing has shown to be successful, but with drop-outs in the HCV cascade of care due to economic reasons that difficulties travel costs to appointments, unconsciousness of disease and low awareness of new direct acting antiviral benefits. In this setting, videoconference as a complement to use of serologic scores and dispensing medication outside the hospital could be useful to improve adherence and reduce drop-outs by reducing the visits to hospital from drug addiction centers (DAC), and promoting direct information regarding benefits of been treated with new antivirals free of interferon directly from specialists.

The hypothesis of the study is that the rate of those diagnosed, fully evaluated of liver disease stage, treated and cured will be improved with a lower rate of drop-outs in the cascade of care in the telemedicine arm compared with the conventional arm without affecting satisfaction in the healthcare assistance process.

This is a prospective, randomized, study in which subjects attending DAC will be invited to participate and sign a consent form.

Aims:

Evaluation of efficacy (compliance rate with the programme which includes completing screening, liver disease evaluation, and treatment)
Evaluation of acceptance (grade of patient satisfaction of the programme)
Evaluation of sustained virological response rate and time to achieve eradication
The adherence rate to follow-up in participants with advanced fibrosis and cirrhosis
To assess factors associated with drop-outs
Cost-effectiveness analysis of the telemedicine programme

Methodology:

The investigators have designed a community-based intervention study to evaluate a telemedicine based programme versus conventional healthcare to all subjects attending DAC and screened for HCV if : a) there is no previous documented HCV antibody request or b) with a previous positive HCV antibody test without viral load (RNA) result or positive result without treatment or confirmed sustained virological response or c) with a negative HCV antibody result tested more than one year ago.

In the conventional arm participants after the dried blood spot (DBS) testing for viral load (RNA) and genotype will be referred to the tertiary care hospital in case of a RNA positive result for a one-day appointment for disease stage evaluation with elastography and prescription of treatment with DBS after12 weeks of finishing treatment for assessing sustained virological response.

In the interventional arm the hepatologist will real-time videoconference with the patient-staff at DAC to discuss the need of DBS for viral load and genotype, evaluation of fibrotic stage by serologic scores and if it is the case in known RNA positive cases prescription of treatment. If DBS is mandatory the patient will be scheduled for a second videoconference to start treatment according to results. Dispensing and custody of treatment will be performed at DAC. Follow-up to assess side effects and sustained virological response will be also scheduled by videoconference.

In both arms when advanced fibrosis or cirrhosis has been detected an appointment at the tertiary care hospital for hepatocellular carcinoma screening will be scheduled every 6 months.

Cost analysis will be performed by investigators to assess medical and non-medical costs and satisfaction of the healthcare model by a validated questionnaire. In all the planned strategies subjects will be asked to complete a questionnaire that includes demographic variables.

For the present study, a 15% improvement in the efficacy (compliance with the programme) was hypothesized in the group of participants receiving the interventional strategy compared to the conventional strategy. Taking into account a power of 80%, alpha error of 5% and losses of 10% will require 83 participants per group.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	166 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Clinical Trial to Evaluate Efficacy and Acceptance of a Telemedicine Based Programme to Treat Hepatitis C Among Patients at Drug Addiction Centers
Actual Study Start Date :	July 5, 2019
Estimated Primary Completion Date :	December 31, 2020
Estimated Study Completion Date :	December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis C

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
No Intervention: Conventional care Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
Active Comparator: Telemedicine care Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers	Behavioral: Telemedicine based healthcare programme Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers

Outcome Measures

Primary Outcome Measures :

Efficacy of the intervention [ Time Frame: 12 months ]
Compliance rate (number of patients of the overall participants) with the programme which includes completing screening, liver disease evaluation, treatment and follow-up visit at 12 week

Secondary Outcome Measures :

Acceptance of the intervention with validated satisfaction questionnaire [ Time Frame: 12 months ]
Grade of patient satisfaction of the telemedicine programme by a validated questionnaire
Sustained virological response rate [ Time Frame: 12 months ]
Achievement of viral eradication rate (number of patients from the total with active infection that received treatment and achieved eradication)
Time to sustained virological response rate [ Time Frame: 12 months ]
Time (months) from DBS testing to achievement of viral eradication
Adherence rate to follow-up [ Time Frame: 12 months ]
Adherence rate (confirmed assistance) to follow-up appointments in patients with advance fibrosis and cirrhosis
Demographic factors associated with drop-outs [ Time Frame: 12 months ]
Evaluation of demographic characteristics associated with drop-outs in the cascade of care
Cost-effectiveness of telemedicine strategy [ Time Frame: 12 months ]
Cost-effectiveness analysis taking in consideration utilities and disease management annual costs of the intervention

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects 18 years old or older with a valid sanitary card in our public health system
Signed Informed consent
Tested for HCV: a) no previous documented HCV antibody request or b) with a previous positive HCV antibody test without RNA result or positive result without treatment or confirmed sustained virological response or c) with a negative HCV antibody result tested more than one year ago
No current surveillance by any hepatitis specialized care (hepatology or internal medicine)

Exclusion Criteria:

Previous DBS testing at DAC lost to follow-up

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04035980

Contacts

Layout table for location contacts

Contact: Manuel N Hernandez-Guerra, MD	34922678559	mhernand@ull.edu.es

Locations

Layout table for location information

Spain
Hospital Universitario de Canarias	Recruiting
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Contact: Manuel Hernandez-Guerra, MD 34922678559 mhernand@ull.edu.es

Sponsors and Collaborators

University of La Laguna

Investigators

Layout table for investigator information

Principal Investigator:	Manuel Hernandez-Guerra, MD	MD

More Information

Publications:

García-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat. 2011 Oct;18(10):e453-60. doi: 10.1111/j.1365-2893.2011.01467.x. Epub 2011 Jun 1.

Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, Espelt A, Bravo MJ; Itinere Project Group. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. J Epidemiol Community Health. 2015 Jun;69(6):599-603. doi: 10.1136/jech-2014-205070. Epub 2015 Apr 13.

Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature. Int J Drug Policy. 2015 Nov;26(11):1050-5. doi: 10.1016/j.drugpo.2015.05.001. Epub 2015 Jun 4. Review.

Layout table for additonal information

Responsible Party:	Manuel Hernandez-Guerra, MD, Principal Investigator, University of La Laguna
ClinicalTrials.gov Identifier:	NCT04035980
Other Study ID Numbers:	Telemedicine_HCV
First Posted:	July 29, 2019 Key Record Dates
Last Update Posted:	July 29, 2019
Last Verified:	July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Manuel Hernandez-Guerra, MD, University of La Laguna:


Screening Telemedicine Diagnosis

Additional relevant MeSH terms:

Layout table for MeSH terms

Hepatitis A Hepatitis C Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human	Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections

To Top